Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments - Segment Information (Details)

v3.20.1
Note 14 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Revenue from contract with customer $ 15,000 $ 14,000  
Grant and other revenue 141,051 38,474  
Revenues, Total 156,272 41,624  
Cost of revenue 609 6,126  
Research and development expenses 999,269 740,583  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,810,911 1,691,737  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 16,843 36,779  
(Loss) income from operations (2,671,360) (2,433,601) [3]  
Other income (expense) (2,248) 8,713  
Net loss (2,673,608) (2,429,061)  
Total assets, net of depreciation and amortization 4,477,231   $ 4,150,906
Capital expenditures 6,459  
Provision for income taxes (876)  
Net loss from continuing operations   (2,425,764)  
Loss from discontinued operations, net of tax   (3,297)  
UNITED STATES      
Total assets, net of depreciation and amortization 4,477,231 4,948,736  
Non-US [Member]      
Total assets, net of depreciation and amortization 11,024  
Royalty [Member]      
Revenue from contract with customer 15,221 3,150  
Diagnostics Segment [Member]      
Grant and other revenue 58,916 35,991  
Revenues, Total 74,137 39,141  
Cost of revenue 609 6,126  
Research and development expenses 957,626 740,583  
Selling, general and administrative expenses, excluding depreciation and amortization [1]  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]  
(Loss) income from operations (884,098) (707,568) [3]  
Other income (expense)  
Net loss (884,098) (711,121)  
Capital expenditures  
Provision for income taxes   (256)  
Net loss from continuing operations   (707,824)  
Loss from discontinued operations, net of tax   (3,297)  
Diagnostics Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 36,671 55,213  
Diagnostics Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization 10,422  
Diagnostics Segment [Member] | Royalty [Member]      
Revenue from contract with customer 15,221 3,150  
Therapeutics Segment [Member]      
Grant and other revenue 82,135 2,483  
Revenues, Total 82,135 2,483  
Cost of revenue  
Research and development expenses 41,643  
Selling, general and administrative expenses, excluding depreciation and amortization [1] (1,522) 11,714  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]  
(Loss) income from operations 42,014 (9,231) [3]  
Other income (expense)  
Net loss 42,014 (9,234)  
Capital expenditures  
Provision for income taxes   (3)  
Net loss from continuing operations   (9,234)  
Loss from discontinued operations, net of tax    
Therapeutics Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 2,494 2,411  
Therapeutics Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization  
Therapeutics Segment [Member] | Royalty [Member]      
Revenue from contract with customer  
Corporate Segment [Member]      
Grant and other revenue  
Revenues, Total  
Cost of revenue  
Research and development expenses  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,812,433 1,680,023  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 16,843 36,779  
(Loss) income from operations (1,829,276) (1,716,802) [3]  
Other income (expense) (2,248) 8,713  
Net loss (1,831,524) (1,708,706)  
Capital expenditures 6,459  
Provision for income taxes   (617)  
Net loss from continuing operations   (1,708,706)  
Loss from discontinued operations, net of tax    
Corporate Segment [Member] | UNITED STATES      
Total assets, net of depreciation and amortization 4,438,066 4,891,112  
Corporate Segment [Member] | Non-US [Member]      
Total assets, net of depreciation and amortization 602  
Corporate Segment [Member] | Royalty [Member]      
Revenue from contract with customer  
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2] Depreciation and amortization is reflected in selling, general and administrative expenses ($144,512 and $150,385 for the years ended December 31, 2019 and 2018, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.